Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sandu Pharmaceuticals Limited is a mid-sized Indian pharmaceutical company focused on the production and distribution of generic medicines and over-the-counter products. Its competitive position is bolstered by a diverse portfolio of products and a strong distribution network across India, which allows it to capture market share in both urban and rural areas.
Sandu Pharmaceuticals generates revenue primarily through the sale of generic drugs, leveraging its cost-effective production processes and established relationships with distributors. The company benefits from pricing power due to its established brand presence and a broad product range, which allows it to maintain competitive margins despite market pressures.
Changes in regulatory policies affecting drug approvals in India
Market share gains in the generic pharmaceuticals sector
Fluctuations in raw material costs impacting gross margins
New product launches or expansions into new therapeutic areas
Regulatory changes that could impact drug pricing and approval processes
Technological disruption in drug manufacturing processes
Intensifying competition from both domestic and international generic drug manufacturers
Potential loss of patent protections on key products
Low liquidity risk due to a current ratio of 2.43
Minimal financial leverage reduces risk exposure
moderate - As a pharmaceutical company, Sandu Pharmaceuticals is somewhat insulated from economic downturns, but consumer spending on healthcare can still be affected by GDP growth.
Low - The company has minimal debt (Debt/Equity of 0.01), so rising interest rates do not significantly impact financing costs. However, higher rates could indirectly affect consumer spending on healthcare products.
minimal - The company's low debt levels indicate limited reliance on credit markets.
value - The low Price/Sales ratio of 0.5x suggests the stock may be undervalued, appealing to value investors.
moderate - The stock has shown a 1-year return of -17.2%, indicating some volatility in its price performance.
